We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

The Time of Positive Conversion of Interferon-γ Releasing Assay After Tuberculosis Exposure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00981071
Recruitment Status : Completed
First Posted : September 22, 2009
Last Update Posted : April 8, 2010
Sponsor:
Information provided by:

Study Description
Brief Summary:
The aim is to evaluate the time of positive conversion after exposure to smear positive pulmonary tuberculosis (TB) in a platoon of Korean military, a closed communal setting.

Condition or disease
Tuberculosis

Detailed Description:
In a platoon where TB outbreak occurred, we performed low dose chest CT (LDCT), QuantiFERON-TB gold in tube (QFT) and two-step (0, 4weeks) TST for outbreak investigation. We perform QFT at 0, 2, 4, 8 and 12 weeks after initial investigation for soldiers with negative QFT results, and soldiers with positive QFT and normal LDCT took isoniazid and rifampin for 3 months as treatment of latent TB.

Study Design

Study Type : Observational
Actual Enrollment : 32 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Time of Positive Conversion of Interferon-γ Releasing Assay After Tuberculosis Exposure
Study Start Date : May 2009
Primary Completion Date : April 2010
Study Completion Date : April 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tuberculosis
Drug Information available for: Interferon
U.S. FDA Resources

Groups and Cohorts

Group/Cohort
A platoon with TB outbreak


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
A military unit in South Korean Army
Criteria

Inclusion Criteria:

  • All soldiers who assigned to the military platoon where a tuberculosis outbreak occurred

Exclusion Criteria:

  • Soldiers who could not complete study or refused the study protocol
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00981071


Sponsors and Collaborators
Armed Forces Capital Hospital, Republic of Korea
Investigators
Principal Investigator: Jae-Joon Yim, MD Seoul National University Hospital
More Information

Responsible Party: Sei Won Lee/Division chief of pulmonology, Armed Forces Capital Hospital
ClinicalTrials.gov Identifier: NCT00981071     History of Changes
Other Study ID Numbers: QFTconversion
First Posted: September 22, 2009    Key Record Dates
Last Update Posted: April 8, 2010
Last Verified: April 2010

Keywords provided by Armed Forces Capital Hospital, Republic of Korea:
Tuberculosis
QuantiFERON
Outbreak
Conversion

Additional relevant MeSH terms:
Tuberculosis
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Interferons
Interferon-gamma
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents